During the 'Heart Failure and World Congress on Acute Heart Failure 2018', many sessions and lectures focused on cardio-oncology. This important field of research is constantly growing, and therefore, a great amount of time during the congress focused on it. Prevention and early recognition of side effects is very important in cancer patients. One of the most common and potentially severe problems during antineoplastic therapy is cardiotoxicity. Hence, cardio-oncology is vital in managing cancer patients. This paper will summarize the topics discussed in three main sessions and many additional lectures throughout the 'Heart Failure and World Congress on Acute Heart Failure 2018'. The covered topics included pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable with different circulating and imaging biomarkers, as well as cardioprotective treatments recommended by different guidelines and position papers.

1st Department of Medicine Cardioangiology Medical Faculty and University Hospital Hradec Králové Czech Republic

Berlin Brandenburg Center for Regenerative Therapies Berlin Germany

Cardio oncology Clinic Heart Failure Unit Department of Cardiology Athens University Hospital 'Attikon' National and Kapodistrian University of Athens Athens Greece

Cardio oncology Unit Cardiac Imaging Unit Department of Cardiology La Paz University Hospital IdiPAz Madrid Spain

Department of Cardiology Cardio oncology Bern University Hospital Bern Switzerland

Department of Cardiology Charité Campus Benjamin Franklin Berlin Germany

Department of Cardiology Lariboisière Hospital Paris France

Department of Cardiology Medical University of Vienna Vienna Austria

Department of Cardiology University of Groningen University Medical Center Groningen Groningen The Netherlands

Department of Cardiology University of Paris 7 Denis Diderot Paris France

Department of Translational Medical Sciences Federico 2 University Naples Italy

Deutsches Zentrum für Herz und Kreislaufforschung Standort Göttingen Göttingen Germany

Division of Cardiology and Metabolism Department of Cardiology Charité Berlin Germany

DZHK partner site Berlin Berlin Germany

Klinik für Kardiologie und Pneumologie Herzzentrum Göttingen Universitätsmedizin Göttingen Georg August Universität Göttingen Germany

Royal Brompton Hospital and Imperial College London London UK

Sechenov Medical University Moscow Russia

U942 INSERM BIOCANVAS Paris France

Univeristy of Cyprus Medical School Nicosia Cyprus

Zobrazit více v PubMed

Zamorano JL, Lancellotti P, Rodruguez Munoz D, Aboyans R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Tamargo J, Torbicki A, Suter ZM, ESC Scientific Document Group . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 2768–2801. PubMed

Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio‐oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation 2015; 132: 2248–2258. PubMed PMC

Angsutararux P, Luanpitpong S, Issaragrisil S. Chemotherapy‐induced cardiotoxicity: overview of the roles of oxidative stress. Oxid Med Cell Longev 2015; 2015: 795602. PubMed PMC

Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig‐Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749–1755. PubMed PMC

Berg DD, Vaduganathan M, Nohria A, Davids MS, Alyea EP, Torre M, Padera RF Jr. Immune‐related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. Eur J Heart Fail 2017; 19: 682–685. PubMed

Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the ‘Silver Tsunami’: prevalence trajectories and co‐morbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 2016; 25: 1029–1036. PubMed PMC

Armenian SH, Lachhetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moleshi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2017; 35: 893–911. PubMed

Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer‐Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, DeCara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhães A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911–939. PubMed

López‐Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P, Velasco Del Castillo S, López de Sá Areses E, Barreiro‐Pérez M, Hinojar Baydes R, Pérez de Isla L, Valbuena López SC, Dalmau González‐Gallarza R, Calvo‐Iglesias F, González Ferrer JJ, Castro Fernández A, González‐Caballero E, Mitroi C, Arenas M, Virizuela Echaburu JA, Marco Vera P, Íñiguez Romo A, Zamorano JL, Plana Gómez JC, López Sendón Henchel JL. Cardio‐onco‐hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed) 2017; 70: 474–486. PubMed

Tamborini G, Piazzese C, Lang RM, Muratori M, Chiorino E, Mapelli M, Fusini L, Ali SG, Gripari P, Pontone G, Andreini D, Pepi M. Feasibility and accuracy of automated software for transthoracic three‐dimensional left ventricular volume and function analysis: comparisons with two‐dimensional echocardiography, three‐dimensional transthoracic manual method, and cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2017; 30: 1049–1058. PubMed

Lang RM, Badano LP, Mor‐Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39 e14. PubMed

Thavendiranathan P, Poulin F, Lim K‐M, Plana JC, Woo A, Marwich TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63: 2751–2768. PubMed

López‐Fernández T, García AM, Beltrán AS, Luis AM, Sanz RG, Ramos PM, del Castillo SV, de Sá Areses EL, Barreiro‐Pérez M, Baydes RH, de Isla LP, López SCV, González‐Gallarza RD, Calvo‐Iglesias F, Ferrer JJG, Fernández AC, González‐Caballero E, Mitroi C, Arenas M, Echaburu JAV, Vera PM, Romo AI, Zamorano JL, Plana Gómez JC, Henchel JLLS. Cardio‐onco‐hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol 2017; 70: 474–486. PubMed

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131: 1981–1988. PubMed

Salem K, ElKhateeb O. Gender‐adjusted and age‐adjusted economic inpatient burden of congestive heart failure: cost and disability‐adjusted life‐year analysis. ESC Heart Fail 2017; 4: 259–265. PubMed PMC

Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C, Kadam UT, Kwok CS, Clark AB, Murchie P, Buchan I, Hannaford PC, Myint PK. Do patients have worse outcomes in heart failure than in cancer? A primary care‐based cohort study with 10‐year follow‐up in Scotland. Eur J Heart Fail 2017; 19: 1095–1104. PubMed

Cohen‐Solal A, Jacobson AF, Piña IL. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Fail 2017; 4: 499–506. PubMed PMC

Yoshihisa A, Watanabe S, Yokokawa T, Misaka T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Takeishi Y. Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction. ESC Heart Fail 2017; 4: 360–364. PubMed PMC

Fornaro A, Olivotto I, Rigacci L, Ciaccheri M, Tomberli B, Ferrantini C, Coppini R, Girolami F, Mazzarotto F, Chiostri M, Milli M, Marchionni N, Castelli G. Comparison of long‐term outcome in anthracycline‐related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail 2018; 20: 898–906. PubMed

Pasco JA, Mohebbi M, Holloway KL, Brennan‐Olsen SL, Hyde NK, Kotowicz MA. Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study. J Cachexia Sarcopenia Muscle 2017; 8: 482–489. PubMed PMC

Martone AM, Bianchi L, Abete P, Bellelli G, Bo M, Cherubini A, Corica F, Di Bari M, Maggio M, Manca GM, Marzetti E, Rizzo MR, Rossi A, Volpato S, Landi F. The incidence of sarcopenia among hospitalized older patients: results from the Glisten study. J Cachexia Sarcopenia Muscle 2017; 8: 907–914. PubMed PMC

Lancellotti P, Galderisi M, Donal E, Edvardsen T, Popescu BA, Farmakis D, Filippatos G, Habib G, Lestuzzi C, Santoro C, Moonen M, Jerusalem G, Andarala M, Anker SD. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Cardiac Oncology Toxicity Long‐Term Registry Investigators. ESC Heart Fail 2017; 4: 312–318. PubMed PMC

Schwaneberg T, Weitmann K, Dösch A, Seyler C, Bahls T, Geidel L, Stahl D, Lee M, Kraus M, Katus HA, Hoffmann W. Data privacy management and data quality monitoring in the German Centre for Cardiovascular Research's multicentre TranslatiOnal Registry for CardiomyopatHies (DZHK‐TORCH). ESC Heart Fail 2017; 4: 440–447. PubMed PMC

Fruhwald F, Lassner D, Fruhwald S, Gross UM, Dapunt O, Schultheiss HP. Immunosuppressive treatment in fulminant myocarditis and gene expression pattern associated with, but no histological confirmation of giant cell myocarditis. ESC Heart Fail 2017; 4: 190–192. PubMed PMC

Sotiropoulos K, Yerly P, Monney P, Garnier A, Regamey J, Hugli O, Martin D, Metrich M, Antonietti JP, Hullin R. Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction. ESC Heart Fail 2016; 3: 198–204. PubMed PMC

Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle 2017; 8: 915–925. PubMed PMC

Paris MT, Lafleur B, Dubin JA, Mourtzakis M. Development of a bedside viable ultrasound protocol to quantify appendicular lean tissue mass. J Cachexia Sarcopenia Muscle 2017; 8: 713–726. PubMed PMC

Spinar J, Jarkovsky J, Spinarova L, Vitovec J, Linhart A, Widimsky P, Miklik R, Zeman K, Belohlavek J, Malek F, Cihalik C, Spac J, Felsoci M, Ostadal P, Dusek L, Kettner J, Vaclavik J, Littnerova S, Monhart Z, Malek J, Parenica J, AHEAD Registry Investigators . Worse prognosis of real‐world patients with acute heart failure from the Czech AHEAD registry in comparison to patients from the RELAX‐AHF trial. ESC Heart Fail 2017; 4: 8–15. PubMed PMC

Vagnildhaug OM, Blum D, Wilcock A, Fayers P, Strasser F, Baracos VE, Hjermstad MJ, Kaasa S, Laird B, Solheim TS, European Palliative Care Cancer Symptom Study Group . The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis. J Cachexia Sarcopenia Muscle 2017; 8: 789–797. PubMed PMC

Rastogi A, Novak E, Platts AE, Mann DL. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid‐range ejection fraction. Eur J Heart Fail 2017; 19: 1597–1605. PubMed PMC

Seyler C, Meder B, Weis T, Schwaneberg T, Weitmann K, Hoffmann W, Katus HA, Dösch A. TranslatiOnal Registry for CardiomyopatHies (TORCH)—rationale and first results. ESC Heart Fail 2017; 4: 209–215. PubMed PMC

Mebazaa A, Motiejunaite J, Gayat E, Crespo‐Leiro MG, Lund LH, Maggioni AP, Chioncel O, Akiyama E, Harjola VP, Seferovic P, Laroche C, Julve MS, Roig E, Ruschitzka F, Filippatos G, ESC Heart Failure Long‐Term Registry Investigators . Long‐term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long‐Term Registry. Eur J Heart Fail 2018; 20: 332–341. PubMed

Nesteruk J, Voronina N, Kundt G, Donndorf P, Klopsch C, Kaminski A, Duckers HJ, Steinhoff G. Stem cell registry programme for patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting: what benefits does it derive? ESC Heart Fail 2017; 4: 105–111. PubMed PMC

Pose A, Almenar L, Gavira JJ, López‐Granados A, Blasco T, Delgado J, Aramburu O, Rodríguez A, Manzano L, Manito N. Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project. ESC Heart Fail 2017; 4: 130–137. PubMed PMC

Rooks DS, Laurent D, Praestgaard J, Rasmussen S, Bartlett M, Tankó LB. Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy. J Cachexia Sarcopenia Muscle 2017; 8: 727–734. PubMed PMC

Loumaye A, de Barsy M, Nachit M, Lause P, van Maanen A, Trefois P, Gruson D, Thissen JP. Circulating activin A predicts survival in cancer patients. J Cachexia Sarcopenia Muscle 2017; 8: 768–777. PubMed PMC

Neefjes ECW, van den Hurk RM, Blauwhoff‐Buskermolen S, van der Vorst MJDL, Becker‐Commissaris A, de van der Schueren MAE, Buffart LM, Verheul HMW. Muscle mass as a target to reduce fatigue in patients with advanced cancer. J Cachexia Sarcopenia Muscle 2017; 8: 623–629. PubMed PMC

Cardinale D, Ciceri F, Franzosi MG LR, Sandri MT, Civelli M, Cucchi G, Menatii E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipollla CM, ICOS‐ONE Study Investigators . Anthracycline‐induced cardiotoxicity: a multicenter randomized trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society‐One trial. Eur J Cancer 2018; 94: 126–137. PubMed

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacorni G, Rubino M, Veglia F, Fiorentini C, Cipolla CM. Anthracycline‐induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55: 213–220. PubMed

Hamo CE, Bloom MW, Cardinale D, Ky B, Nohria A, Baer L, Skopicki H, Lenihan DJ, Gheorghiade M, Lyon AR, Butler J. Cancer therapy‐related cardiac dysfunction and heart failure part 2: prevention, treatment, guidelines, and future directions. Circ Heart Fail 2016; 9: e002843. PubMed PMC

Banke A, Fosbøl EL, Møller JE, Gislason GH, Andersen M, Bernsdorf M, Jensen MB, Schou M, Ejlertsen B. Long‐term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. Eur J Heart Fail 2018; 20: 1447–1453. PubMed

O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Alland L, Tendler C, CAELYX Breast Cancer Study Group . Reduced cardiotoxicity and efficiacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first‐line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440–449. PubMed

De Azambuja E, Procter MJ, van Velduisen DJ, Agbor‐Tarh D, Metzger‐Filho O, Steinseifer J, Untch J, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland‐Jones B, Dowsett M, Gelber RD, Piccart‐Gebhart MJ, Suter TM. Trastuzumab‐associated cardiac events at 8 years of median follow‐up in the Herceptin Adjuvant trial (BIG1‐01). J Klein Oncol 2014; 32: 2159–2165. PubMed

Pivor X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie‐Lacourtoisie S, Tubiana‐Mathieru N, Cany S, Khayat D, Pauporté I, Kramar A, PHARE Trial Investigators . 6 months versus 12 months of adjuvant trastuzumab for patients with HER2‐positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol 2013; 14: 741–748. PubMed

Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G. Reframing the association and significance of co‐morbidities in heart failure. Eur J Heart Fail 2016; 18: 744–758. PubMed

Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, Anker SD. Heart failure epidemiology and novel treatments in Japan: facts and numbers. ESC Heart Fail 2016; 3: 145–151. PubMed PMC

Núñez J, Monmeneu JV, Mollar A, Núñez E, Bodí V, Miñana G, García‐Blas S, Santas E, Agüero J, Chorro FJ, Sanchis J, López‐Lereu MP. Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study. ESC Heart Fail 2016; 3: 293–298. PubMed PMC

Theidel U, Väätäinen S, Martikainen J, Soini E, Hardt T, Doehner W. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC Heart Fail 2017; 4: 274–281. PubMed PMC

Clevenger B, Gurusamy K, Klein AA, Murphy GJ, Anker SD, Richards T. Systematic review and meta‐analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review. Eur J Heart Fail 2016; 18: 774–785. PubMed

Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113: 2454–2461. PubMed

Parissis J, Nikolaou M, Mebazaa A. The model for end‐stage liver disease score in acute heart failure: hepatorenal dysfunction hides behind. Eur J Heart Fail 2016; 18: 1522–1523. PubMed

Koyama S, Kuragaichi T, Sato Y, Kuwabara Y, Usami S, Horie T, Baba O, Hakuno D, Nakashima Y, Nishino T, Nishiga M, Nakao T, Arai H, Kimura T, Ono K. Dynamic changes of serum microRNA‐122‐5p through therapeutic courses indicates amelioration of acute liver injury accompanied by acute cardiac decompensation. ESC Heart Fail 2017; 4: 112–121. PubMed PMC

Ikeda S, Ohshima K, Miyazaki S, Kadota H, Shimizu H, Ogimoto A, Hamada M. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure. ESC Heart Fail 2017; 4: 614–622. PubMed PMC

Sokolski M, Zymliński R, Biegus J, Siwołowski P, Nawrocka‐Millward S, Todd J, Yerramilli MR, Estis J, Jankowska EA, Banasiak W, Ponikowski P. Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. Eur J Heart Fail 2017; 19: 760–767. PubMed

Pietrock C, von Haehling S. Sleep‐disordered breathing in heart failure: facts and numbers. ESC Heart Fail 2017; 4: 198–202. PubMed PMC

Savage HO, Khushaba RN, Zaffaroni A, Colefax M, Farrugia S, Schindhelm K, Teschler H, Weinreich G, Grueger H, Neddermann M, Heneghan C, Simonds A, Cowie MR. Development and validation of a novel non‐contact monitor of nocturnal respiration for identifying sleep‐disordered breathing in patients with heart failure. ESC Heart Fail 2016; 3: 212–219. PubMed PMC

Staszewsky L, Cortesi L, Tettamanti M, Dal Bo GA, Fortino I, Bortolotti A, Merlino L, Latini R, Roncaglioni MC, Baviera M. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. Eur J Heart Fail 2016; 18: 840–848. PubMed

Coiro S, Girerd N, Rossignol P, Ferreira JP, Maggioni A, Pitt B, Tritto I, Ambrosio G, Dickstein K, Zannad F. Association of beta‐blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched‐cohort analysis from the High‐Risk Myocardial Infarction Database Initiative. Eur J Heart Fail 2017; 19: 271–279. PubMed

Koutsampasopoulos K, Ziakas A, Vogiatzis I. Sexual function of patients with heart failure: distinct phenotypes, distinct sexual function? ESC Heart Fail 2017; 4: 319. PubMed PMC

Jaarsma T. Sexual function of patients with heart failure: facts and numbers. ESC Heart Fail 2017; 4: 3–7. PubMed PMC

von Haehling S, Anker MS, Anker SD. Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016. J Cachexia Sarcopenia Muscle 2016; 7: 507–509. PubMed PMC

Clark AL, Coats AJS, Krum H, Katus HA, Mohacsi P, Salekin D, Schultz MK, Packer M, Anker SD. Effect of beta‐adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial. J Cachexia Sarcopenia Muscle 2017; 8: 549–556. PubMed PMC

Sente T, Van Berendoncks AM, Hoymans VY, Vrints CJ. Adiponectin resistance in skeletal muscle: pathophysiological implications in chronic heart failure. J Cachexia Sarcopenia Muscle 2016; 7: 261–274. PubMed PMC

Barazzoni R, Gortan Cappellari G, Palus S, Vinci P, Ruozi G, Zanetti M, Semolic A, Ebner N, von Haehling S, Sinagra G, Giacca M, Springer J. Acylated ghrelin treatment normalizes skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rat chronic heart failure. J Cachexia Sarcopenia Muscle 2017; 8: 991–998. PubMed PMC

Saitoh M, Dos Santos MR, Emami A, Ishida J, Ebner N, Valentova M, Bekfani T, Sandek A, Lainscak M, Doehner W, Anker SD, von Haehling S. Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF). ESC Heart Fail 2017; 4: 448–457. PubMed PMC

Morley JE. Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia. J Cachexia Sarcopenia Muscle 2017; 8: 523–526. PubMed PMC

Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, Kaschina E, Palus S, Pötsch M, von Websky K, Hocher B, Latouche C, Jaisser F, Morawietz L, Coats AJ, Beadle J, Argiles JM, Thum T, Földes G, Doehner W, Hilfiker‐Kleiner D, Force T, Anker SD. Prevention of liver cancer cachexia‐induced cardiac wasting and heart failure. Eur Heart J 2014; 35: 932–941. PubMed PMC

Versace VL, Berry NM, Chowdhury MH, Ullah S, McCarthy AL, Atherton JJ, Koczwara B, Roder D, Clark RA. Characteristics of patients with haematological and breast cancer (1996–2009) who died of heart failure‐related causes after cancer therapy. ESC Heart Fail 2016; 3: 253–260. PubMed PMC

Banke A, Schou M, Videbæk L, Møller JE, Torp‐Pedersen C, Gustafsson F, Dahl JS, Køber L, Hildebrandt PR, Gislason GH. Incidence of cancer in patients with chronic heart failure: a long‐term follow‐up study. Eur J Heart Fail 2016; 18: 260–266. PubMed

Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ, Cerhan JR, Roger VL. Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol 2013; 62: 881–886. PubMed PMC

Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation 2016; 133: 1104–1114. PubMed PMC

Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler‐Klein J, Cohen‐Solal A, Farmakis D, López‐Fernández T, Lainscak M, Pudil R, Ruschitska F, Seferovic P, Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, Tocchetti CG, Heart Failure Association Cardio‐oncology Study Group of the European Society of Cardiology . Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 2018; 20: 879–887. PubMed

Vaduganathan M, Prasad V. Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication? Eur J Heart Fail 2016; 18: 128–132. PubMed

Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA. The failing heart stimulates tumor growth by circulating factors. Circulation 2018; 138: 678–691. PubMed

Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011; 3: 64. PubMed PMC

Nadruz W, West E, Sengeløv M, Grove GL, Santos M, Groarke JD, Forman DE, Claggett B, Skali H, Nohria A, Shah AM. Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. Heart 2018. PubMed PMC

Schäfer M, Oeing CU, Rohm M, Baysal‐Temel E, Lehmann LH, Bauer R, Volz HC, Boutros M, Sohn D, Sticht C, Gretz N, Eichelbaum K, Werner T, Hirt MN, Eschenhagen T, Müller‐Decker K, Strobel O, Hackert T, Krijgsveld J, Katus HA, Berriel Diaz M, Backs J, Herzig S. Ataxin‐10 is part of a cachexokine cocktail triggering cardiac metabolic dysfunction in cancer cachexia. Mol Metab 2015; 5: 67–78. PubMed PMC

Barkhudaryan A, Scherbakov N, Springer J, Doehner W. Cardiac muscle wasting in individuals with cancer cachexia. ESC Heart Fail 2017; 4: 458–467. PubMed PMC

Loncar G, Springer J, Anker M, Doehner W, Lainscak M. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle 2016; 7: 246–260. PubMed PMC

Pavo N, Raderer M, Hülsmann M, Neuhold S, Adlbrecht C, Strink G, Goliasch G, Gisslinger H, Steger GG, Hejna M, Köstler W, Zöchbauer‐Müller S, Marosi C, Kornek G, Auerbach L, Schneider S, Parschalk B, Scheithauer W, Pirker R, Drach J, Zielinski C, Pacher R. Cardiovascular biomarkers in patients with cancer and their association with all‐cause mortality. Heart 2015; 101: 1874–1880. PubMed

Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, Sandek A, Valentova M, Stojakovic T, Scharnagl H, Riess H, Anker SD, von Haehling S. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol 2014; 13: 1310–1319. PubMed

Anker MS, Ebner N, Hildebrandt B, Springer J, Sinn M, Riess H, Anker SD, Landmesser U, Haverkamp W, von Haehling S. Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non‐small cell lung cancer: results of a prospective cardiovascular long‐term study. Eur J Heart Fail 2016; 18: 1524–1534. PubMed

van Bilsen M, Patel HC, Bauersachs J, Böhm M, Borggrefe M, Brutsaert D, Coats AJS, de Boer RA, de Keulenaer GW, Filippatos GS, Floras J, Grassi G, Jankowska EA, Kornet L, Lunde IG, Maack C, Mahfoud F, Pollesello P, Ponikowski P, Ruschitzka F, Sabbah HN, Schultz HD, Seferovic P, Slart RHJA, Taggart P, Tocchetti CG, Van Laake LW, Zannad F, Heymans S, Lyon AR. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2017; 19: 1361–1378. PubMed

Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med 2016; 375: 1457–1467. PubMed

Moslehi J, Amgalan D, Kitsis RN. Grounding cardio‐oncology in basic and clinical science. Circulation 2017; 136: 3–5. PubMed PMC

Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini E, Pirozzi F, Rossi L, Franco I, Bornbaum J, Heger J, Rohrbach S, Perino A, Tocchetti CG, Lima BHF, Teixeira MM, Porporato PE, Schulz R, Angelini A, Sandri M, Ameri P, Sciarretta S, Lima‐Júnior RCP, Mongillo M, Zaglia T, Morello F, Novelli F, Hirsch E, Ghigo A. Phosphoinositide 3‐kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation 2018; 138: 696–711. PubMed

Tocchetti CG, Galdiero MR, Varricchi G. Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio‐immuno‐oncology. J Am Coll Cardiol 2018; 71: 1765–1767. PubMed

Sysa‐Shah P, Tocchetti CG, Gupta M, Rainer PP, Shen X, Kang BH, Belmonte F, Li J, Xu Y, Guo X, Bedja D, Gao WD, Paolocci N, Rath R, Sawyer DB, Naga Prasad SV, Gabrielson K. Bidirectional cross‐regulation between ErbB2 and β‐adrenergic signalling pathways. Cardiovasc Res 2016; 109: 358–373. PubMed PMC

Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, Sullivan RJ, Damrongwatanasuk R, Chen CL, Gupta D, Kirchberger MC, Awadalla M, Hassan MZO, Moslehi JJ, Shah SP, Ganatra S, Thavendiranathan P, Lawrence DP, Groarke JD, Neilan TG. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018; 71: 1755–1764. PubMed PMC

Pokorna Z, Brazdova P, Jirkovsky E, Adamcova M, Mazurova Y, Štěrba M. Study of cardioprotective effects of the ACE inhibitor perindopril against chronic anthracycline cardiotoxicity on dexrazoxane‐validated in vivo model. Poster no. P1309. Eur J Heart Fail 2018; 20: 5–638. PubMed

Bosch X, Rovira M, Sitges M, Domènech A, Ortiz‐Pérez JT, de Caralt TM, Morales‐Ruiz M, Perea RJ, Monzó M, Esteve J. Enalapril and carvedilol for preventing chemotherapy‐induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 2013; 61: 2355–2362. PubMed

Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz‐Menger MW, Gravdehaug B, von Knobelsdorff‐Brenkenhoff F, Bratland Am Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo‐controlled, double‐blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37: 1671–1680. PubMed PMC

Jirkovská‐Vávrová A, Roh J, Lenčová‐Popelová O, Jirkovský E, Hrušková K, Potůčková‐Macková E, Jansová H, Hašková P, Martinková P, Eisner T, Kratochvíl M, Šůs J, Macháček M, Vostatková‐Tichotová L, Geršl V, Kalinowski DS, Muller MT, Richardson DR, Vávrová KI, Štěrba M, Šimůnek T. Synthesis and analysis of novel analogues of dexrazoxane and its open‐ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo . Toxicol Res 2015; 4: 1098–1114.

Schroeder PE, Hasinoff BB. The doxorubicin‐cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion‐chelating form ADR‐925. Cancer Chemother Pharmacol 2002; 50: 509–513. PubMed

Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, William J, Hyman RDA, Mennel RG, Boehm KA, Meyer LAWG, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7‐year follow‐up of US Oncology Research Trial 9735. J Clin Oncol 2009; 27: 1177–1183. PubMed

Bovelli D, Plataniotis G, Roila F. On behalf of the ESMO Guidelines Working Group; Cardiotoxicity of chemotherapeutic agents and radiotherapy‐related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21:277–282. PubMed

Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Clin Oncol 2017; 13: 270–275. PubMed

Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2008; Art. No.: CD003917. PubMed

Avila MS, Ayub‐Ferreira SM, de Barros Wanderley MR Jr, des Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, Higuchi‐Dos‐Santos MH, Hajjar LA, Kalli Filho PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA. Carvedilol for prevention of chemotherapy‐related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 2018; 71: 2281–2290. PubMed

Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'